Table 2.
USP1 over/underexpression in several cancer tissue types
| Cancer type | Overexpressed | Underexpressed |
|---|---|---|
| Sarcoma |
11/15 (73%) |
0/15 (0%) |
| Melanoma |
4/6 (67%) |
1/6 (17%) |
| Gastric cancer |
5/8 (63%) |
0/8 (0%) |
| Cervical cancer |
3/5 (60%) |
0/5 (0%) |
| Brain and CNS cancer |
10/20 (50%) |
1/20 (5%) |
| Liver cancer |
3/10 (30%) |
0/10 (0%) |
| Other cancer |
8/27 (30%) |
6/27 (22%) |
| Lung cancer |
4/16 (25%) |
0/16 (0%) |
| Bladder cancer |
2/9 (22%) |
0/9 (0%) |
| Myeloma |
1/5 (20%) |
0/5 (0%) |
| Colorectal cancer |
5/26 (19%) |
0/26 (0%) |
| Head and neck cancer |
4/25 (16%) |
0/25 (0%) |
| Esophageal cancer |
1/10 (10%) |
0/10 (0%) |
| Kidney cancer |
2/20 (10%) |
0/20 (0%) |
| Ovarian cancer |
1/11 (9%) |
1/11 (9%) |
| Lymphoma |
2/27 (7%) |
3/27 (11%) |
| Breast cancer |
1/31 (3%) |
1/31 (3%) |
| Leukemia |
0/22 (0%) |
4/22 (18%) |
| Pancreatic cancer |
0/8 (0%) |
0/8 (0%) |
| Prostate cancer | 0/16 (0%) | 1/16 (6%) |
The publicly avalilable Oncomine cancer microarray database (accessed in April 2013) was queried to systematically assess USP1 expression levels across different cancer types versus the corresponding normal tissue (Analysis type: Cancer vs Normal). In the “Gene summary view” page, the following thresholds were set: P-value < 0.05; Fold-change > 1.5; Gene-rank, Top 10%. As “Data-type”, mRNA was selected. For each cancer type, the number of analyses that met the thresholds for overexpression or underexpression was recorded, and is shown in the Table as a ratio (and percentage) with respect to the total number of analyses in the database.